Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

BridgeBio Pharma (BBIO) FCF Margin: 2019-2025

Historic FCF Margin for BridgeBio Pharma (BBIO) over the last 7 years, with Sep 2025 value amounting to -91.17%.

  • BridgeBio Pharma's FCF Margin rose 652314.00% to -91.17% in Q3 2025 from the same period last year, while for Sep 2025 it was -165.62%, marking a year-over-year increase of 4173.00%. This contributed to the annual value of -235.09% for FY2024, which is 545153.00% up from last year.
  • Per BridgeBio Pharma's latest filing, its FCF Margin stood at -91.17% for Q3 2025, which was down 24.54% from -73.20% recorded in Q2 2025.
  • BridgeBio Pharma's FCF Margin's 5-year high stood at 16,437.47% during Q4 2021, with a 5-year trough of -40,213.61% in Q3 2022.
  • For the 3-year period, BridgeBio Pharma's FCF Margin averaged around -2,955.29%, with its median value being -3,321.54% (2024).
  • Over the last 5 years, BridgeBio Pharma's FCF Margin had its largest YoY gain of 9,709,895bps in 2021, and its largest YoY loss of 3,526,199bps in 2021.
  • BridgeBio Pharma's FCF Margin (Quarterly) stood at 16,437.47% in 2021, then plummeted by 2,146,656bps to -5,029.09% in 2022, then tumbled by 214,879bps to -7,177.88% in 2023, then soared by 385,634bps to -3,321.54% in 2024, then surged by 652,314bps to -91.17% in 2025.
  • Its last three reported values are -91.17% in Q3 2025, -73.20% for Q2 2025, and -171.11% during Q1 2025.